Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".

clinical practice guideline individual fitness score (IFS) prescription quality indicator schizophrenia

Journal

Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700

Informations de publication

Date de publication:
12 2022
Historique:
revised: 24 08 2022
received: 16 07 2022
accepted: 30 08 2022
pubmed: 19 10 2022
medline: 24 12 2022
entrez: 18 10 2022
Statut: ppublish

Résumé

The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence-practice-gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. IFS points vary and ranged from 0 to100. The average pre-admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.

Identifiants

pubmed: 36254805
doi: 10.1002/npr2.12293
pmc: PMC9773743
doi:

Substances chimiques

Antipsychotic Agents 0

Banques de données

UMIN-CTR
['UMIN000022645']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

502-509

Informations de copyright

© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

Références

World J Biol Psychiatry. 2012 Jul;13(5):318-78
pubmed: 22834451
BJPsych Open. 2022 Apr 21;8(3):e83
pubmed: 35446248
Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324
pubmed: 34390232
Psychiatry Clin Neurosci. 2019 Oct;73(10):642-648
pubmed: 31437336
Sleep Med. 2022 Jan;89:23-30
pubmed: 34875519
Neuropsychopharmacol Rep. 2022 Mar;42(1):3-9
pubmed: 34854260
Neuropsychopharmacol Rep. 2021 Jun;41(2):199-206
pubmed: 33704931
Psychiatry Res. 2021 Mar;297:113764
pubmed: 33567393
Neuropsychopharmacol Rep. 2022 Dec;42(4):502-509
pubmed: 36254805
Neuropsychopharmacol Rep. 2020 Sep;40(3):281-286
pubmed: 32602667
Asian J Psychiatr. 2022 Mar;69:103007
pubmed: 35051727
Asian J Psychiatr. 2021 Sep;63:102744
pubmed: 34325252
Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669
pubmed: 32881226
Can J Psychiatry. 2017 Sep;62(9):624-634
pubmed: 28886671
J Hepatobiliary Pancreat Sci. 2022 Oct;29(10):1057-1083
pubmed: 35388634
Med J Aust. 2017 Jun 19;206(11):501-505
pubmed: 28918734

Auteurs

Ken Inada (K)

Department of Psychiatry, School of Medicine, Kitasato University, Sagamihara, Japan.

Kentaro Fukumoto (K)

Department of Neuropsychiatry, Iwate Medical University, Iwate, Japan.

Naomi Hasegawa (N)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.

Yuka Yasuda (Y)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan.

Hisashi Yamada (H)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
Department of Neuropsychiatry, Hyogo Medical College, Hyogo, Japan.

Hikaru Hori (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Kayo Ichihashi (K)

Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan.

Hitoshi Iida (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Kazutaka Ohi (K)

Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan.

Hiroyuki Muraoka (H)

Department of Psychiatry, School of Medicine, Kitasato University, Sagamihara, Japan.
Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Fumitoshi Kodaka (F)

Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.

Kenta Ide (K)

Department of Hospital Pharmacy, Hospital of University of Occupational and Environmental Health, Fukuoka, Japan.

Naoki Hashimoto (N)

Department of Psychiatry, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.

Jun-Ichi Iga (JI)

Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Ehime, Japan.

Kazuyoshi Ogasawara (K)

Center for Postgraduate Clinical Training and Career Development, Nagoya University Hospital, Achi, Japan.

Kiyokazu Atake (K)

Nippon Telegraph and Telephone West Corporation Kyushu Health Administration Center, Fukuoka, Japan.

Yoshikazu Takaesu (Y)

Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

Tatsuya Nagasawa (T)

Department of NeuroPsychiatry Kanazawa Medical University, Ishikawa, Japan.

Hiroshi Komatsu (H)

Department of Psychiatry, Tohoku University Hospital, Miyagi, Japan.

Tsuyoshi Okada (T)

Department of Psychiatry, Jichi Medical University, Tochigi, Japan.

Ryuji Furihata (R)

Agency for Student Support and Disability Resources, Kyoto University, Kyoto, Japan.

Mikio Kido (M)

Kido Clinic, Toyama, Japan.
Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.

Saya Kikuchi (S)

Department of Psychiatry, Tohoku University Hospital, Miyagi, Japan.

Chika Kubota (C)

Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.

Manabu Makinodan (M)

Department of Psychiatry, Nara Medical University, Nara, Japan.

Shinichiro Ochi (S)

Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, Japan.
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Alabama, USA.

Masahiro Takeshima (M)

Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.

Hirotaka Yamagata (H)

Division of Neuropsychiatry, Department of Neuroscience Yamaguchi University School of Medicine, Yamaguchi, Japan.

Junya Matsumoto (J)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.

Kenichiro Miura (K)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.

Masahide Usami (M)

Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.

Taishiro Kishimoto (T)

Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan.

Toshiaki Onitsuka (T)

Department of Neuroimaging Psychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Eiichi Katsumoto (E)

Katsumoto Mental Clinic, Osaka, Japan.

Akitoyo Hishimoto (A)

Department of Psychiatry, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Shusuke Numata (S)

Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan.

Norio Yasui-Furukori (N)

Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan.

Koichiro Watanabe (K)

Department of Neuropsychiatry, School of Medicine, Kyorin University, Tokyo, Japan.

Ryota Hashimoto (R)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH